FDA, Mayo Clinic, and 400 Patients: How EYE TELL Builds Evidence

Building Evidence, Not Seeking Shortcuts: The Real Meaning Behind FDA Breakthrough Device Status

When EYE TELL received FDA Breakthrough Device designation, it signaled something fundamental about how regulators view our technology—but the real story goes deeper than the label itself. The distinction matters, especially in a digital health landscape where companies often chase approval pathways as their primary goal. We're taking a different approach: building rigorous, peer-reviewed evidence that transforms how early detection works.

FDA Breakthrough Device status acknowledges that a technology addresses an unmet clinical need with the potential to provide more effective treatment or diagnosis than existing alternatives. For EYE TELL, this recognition came because we demonstrated that analyzing pupil diameter, pupil reactivity, and related biometric markers through a standard smartphone could detect six distinct conditions—from Parkinson's disease to concussion—in under 30 seconds, without hardware. But receiving this status is not our endpoint; it's validation that we're asking the right questions.

From 400+ Patients to Clinical Credibility

The 400+ patients who have participated in EYE TELL research represent the foundation of something increasingly rare in digital health: independent clinical validation. Each participant undergoes both our smartphone-based pupil analysis and traditional clinical assessments, creating a comparative dataset. This isn't internal marketing data—it's evidence being scrutinized by the medical community.

Our collaboration with Mayo Clinic exemplifies this commitment. One of North America's leading medical institutions doesn't lend its name to unproven concepts. Their involvement means our algorithms are being tested against established diagnostic standards, our sensitivity and specificity are being measured against gold-standard methods, and our results are being examined by clinicians who have no commercial stake in our success. When Mayo Clinic validates a digital biomarker, it carries weight in both clinical and regulatory spheres.

This evidence-building approach addresses a critical gap in digital health. Too many applications claim to detect disease early but lack the independent validation that physicians need to trust them. We're inverting that dynamic: prove the science first, build the approval case second.

Why Evidence, Not Approval, Matters First

The distinction between "seeking FDA approval" and "building clinical evidence" reflects our core philosophy. FDA De Novo submission—our planned regulatory path—requires robust data demonstrating safety and effectiveness. But clinician adoption, insurance coverage, and genuine integration into preventive care workflows depend on something broader: credibility within the medical community.

Early detection only creates value when the detected condition leads to action—a patient gets screened further, sees a specialist, begins monitoring for progression. This clinical pathway requires trust. Healthcare providers won't integrate a screening tool into their practice because it has a regulatory label; they'll do it because peer-reviewed journals, hospital systems, and professional guidelines say the tool reliably identifies at-risk populations.

By prioritizing evidence over expedited approval timelines, we're building the foundation for genuine clinical adoption. The 400+ patient cohort, combined with Mayo Clinic's validation, creates a narrative that regulators, clinicians, and health systems all understand: this technology has been tested rigorously and produces results.

Our mission at EYE TELL centers on transforming how humanity detects disease early—before symptoms emerge, before progression advances. FDA Breakthrough status confirms we're on the right track. But the real breakthrough comes when our technology helps a person discover a condition years earlier, when intervention is most effective. That requires evidence that convinces not just agencies, but the entire healthcare ecosystem. That's what we're building.

Try It Now — 30 Seconds, No Hardware Required

Just your smartphone camera. No app download. No appointment needed.See what your pupils reveal about your health in real time.

→ Try EYE TELL Free

Prevention starts with awareness. Your pupils are already telling the story.